Skip to main content

04/08/22

Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022

Media

Discovery and characterization of a PI3KαH1047X mutant selective inhibitor with a best-in-class profile